Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China
· Delayed Price · Currency is CNY 21.92
+0.04 (0.18%)
May 23, 2025, 2:45 PM CST
Nanjing Vazyme Biotech Revenue
Nanjing Vazyme Biotech had revenue of 284.98M CNY in the quarter ending March 31, 2025, a decrease of -5.50%. This brings the company's revenue in the last twelve months to 1.36B, up 5.91% year-over-year. In the year 2024, Nanjing Vazyme Biotech had annual revenue of 1.38B with 7.15% growth.
Revenue (ttm)
1.36B
Revenue Growth
+5.91%
P/S Ratio
6.38
Revenue / Employee
474.82K
Employees
2,867
Market Cap
8.69B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 39.59B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |